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Abstract
Background: In this study, we sought to compare the performance of spondyloarthritis (SpA) classification criteria
sets in an international SpA cohort with patients included from five continents around the world.
Methods: Data from the (ASAS) COMOrbidities in SPondyloArthritis (ASAS-COMOSPA) study were used. ASAS-
COMOSPA is a multinational, cross-sectional study with consecutive patients diagnosed with SpA by
rheumatologists worldwide. Patients were classified according to the European Spondyloarthropathy Study Group
(ESSG), modified European Spondyloarthropathy Study Group (mESSG), Amor, modified Amor, Assessment of
SpondyloArthritis international Society (ASAS) axial Spondyloarthritis (axSpA), ASAS peripheral spondyloarthritis
(pSpA) and ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria. Overlap between the classification criteria
sets was assessed for patients with and without back pain. Furthermore, patients fulfilling different arms of the
ASAS axSpA criteria (imaging arm, clinical arm, both arms) were compared on the presence of SpA features.
Results: A total of 3942 patients (5 continents, 26 countries) were included. The mean age was 43.6 years, 65.0%
were male, 56.2% were human leucocyte antigen B27-positive and 64.4% had radiographic sacroiliitis (based on
modified New York criteria). Of the patients, 85.5% were classified by the ASAS SpA criteria (87.7% ASAS axSpA,
12.3% ASAS pSpA). Fulfilment of the Amor, ESSG and CASPAR criteria was present in 83.3%, 88.4% and 21.6% of
patients, respectively. Of the patients with back pain (n = 3227), most were classified by all three of Amor, ESSG and
ASAS axSpA criteria (71.4%). Patients fulfilling the imaging arm and the clinical arm of the ASAS axSpA criteria had
similar presentations of SpA features. In patients without back pain, overlap between classification criteria sets was
seen, although to a lesser extent.
Conclusions: Most patients with a clinical diagnosis of axial SpA in the worldwide ASAS-COMOSPA study fulfil
several classification criteria sets, and a substantial overlap between different criteria sets is seen, which suggests a
high level of credibility of the criteria. Large inter-regional differences in the fulfilment of classification criteria were
not found. Patients fulfilling the clinical arm were remarkably similar to patients fulfilling the imaging arm with
respect to the presence of most SpA features.
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Background
Spondyloarthritis (SpA) encompasses a group of inter-
related rheumatic conditions: ankylosing spondylitis
(AS), including earlier forms of the disease that do not
yet exhibit definitive structural damage on radiographs;
psoriatic arthritis (PsA); arthritis associated with inflam-
matory bowel disease (IBD); and reactive arthritis [1].
Because SpA may have a heterogeneous presentation, a
correct diagnosis is challenging. Rheumatologists make a
diagnosis on the basis of what they have been taught
during rheumatology training. The ‘art of diagnosing’
starts with a list of potential differential diagnoses, from
among which the trained clinician deducts the most
appropriate disease based upon the recognition of the
‘Gestalt’ and exclusion of other diagnoses.
Classification serves a completely different purpose,
and several classification criteria sets of SpA are avail-
able. These classification criteria should be applied only
in patients who have been diagnosed with SpA by a
rheumatologist, and they cannot be used as a check box
to be ticked in order to make the diagnosis. But the
components of classification criteria may remind the
clinician of the clinical picture of the disease. Different
criteria sets put an emphasis on different features, and
we do not know to what extent different criteria sets
have penetrated different parts of the world. Therefore,
we do not know which sets have influenced clinicians in
particular regions most or to what extent these various
sets of criteria describe more or less similar patients.
Consequently, we do not know if rheumatologists
around the world diagnose patients with a similar
clinical picture of the disease.
The European Spondyloarthropathy Study Group
(ESSG) criteria and the Amor criteria were developed to
classify patients with SpA as a whole [2, 3]. In clinical
practice, rheumatologists tend to distinguish patients
with SpA according to their primary clinical presenta-
tion as patients with predominantly axial or predomin-
antly peripheral complaints (with some overlap between
these subtypes). The Assessment of SpondyloArthritis
international Society (ASAS) has developed new criteria
to better accommodate this distinction [4, 5]. These
criteria sets can classify patients with predominantly
axial symptoms as having axial spondyloarthritis (axSpA)
and patients with predominantly peripheral symptoms
as having peripheral spondyloarthritis (pSpA). The ASAS
axSpA criteria consist of two arms: the imaging arm
classifies patients who have sacroiliitis visualised on con-
ventional radiographs and/or bone marrow oedema on
magnetic resonance imaging (MRI), and the clinical arm
classifies patients with normal imaging results. In 2006,
a specific classification criteria set for PsA was devel-
oped, known as the ClASsification criteria for Psoriatic
ARthritis (CASPAR) [6].
Classification criteria are used to include patients in
clinical trials, cohort studies and other types of research.
These criteria are frequently validated in restricted pa-
tient populations. We took the opportunity to investigate
if rheumatologists worldwide diagnosed similar types of
patients as having SpA by testing if patients fulfil similar
criteria sets in the Assessment of SpondyloArthritis
international Society COMOrbidities in SPondyloArthri-
tis (ASAS-COMOSPA) study. Our assumption was that
the more criteria sets a patient fulfils, the higher the
likelihood that a patient with a diagnosis of SpA truly
has SpA. The ASAS-COMOSPA study provides a
unique opportunity to investigate this research question
because it is, to our knowledge, the first observational
study with such a large, worldwide population of pa-
tients with SpA, with axial and/or peripheral symptoms
included [7].
Methods
Study population
The ASAS-COMOSPA study is an observational, cross-
sectional, multicentre study which has been introduced
elsewhere [7]. Participating rheumatologists were asked
to include consecutive patients with a diagnosis of SpA
from routine care. These patients had to fulfil the ASAS
axSpA or pSpA criteria, but fulfilment of the ASAS
criteria was not checked before inclusion. All informa-
tion required to judge the fulfilment of various criteria
sets, including the ASAS criteria, was collected in a
random order (not grouped by criteria set) in the case
report form.
Patients from 26 participating countries in 6 regions
across the world (Western Europe, Central Europe, North
America, Latin America, North Africa and Asia) were
included. Western Europe was represented by Belgium,
France, Germany, Hungary, Italy, the Netherlands, Portugal,
Spain and the United Kingdom. Poland, Russia, Turkey and
Ukraine were grouped into Central Europe. North America
encompasses Canada and the United States, and Argentina,
Brazil, Colombia and Mexico were summarized as Latin
America. North Africa comprised Egypt and Morocco.
China, Japan, Korea, Singapore and Taiwan were grouped
and referred to as Asia. Approval by the local medical ethics
committees, as well as written informed consent from all
patients, was obtained before inclusion.
Classification criteria
Patients were classified according to the following cri-
teria sets: ESSG, Amor, ASAS SpA, ASAS axSpA, ASAS
pSpA, imaging arm of ASAS axSpA, clinical arm of
ASAS axSpA and CASPAR criteria [8]. The presence of
either inflammatory back pain (IBP) or peripheral arth-
ritis is a mandatory entry criterion of the ESSG criteria.
According to the ESSG criteria, patients with at least
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one of the entry criteria in combination with one other
minor criterion, such as enthesitis or psoriasis, are
classified as having SpA [2]. Human leukocyte antigen
B27 (HLA-B27) is not incorporated in this criteria set.
The Amor criteria include a list of features with different
weights, none of which is essential to classify a patient
as having SpA, but a classification of SpA depends on
the sum of weights [3]. Because patients in the
COMOSPA study were not asked about the presence of
balanitis, night pain and buttock pain, these items have
not been taken into account, and therefore patients can-
not collect points on these items in the Amor and ESSG
criteria. The ESSG and Amor criteria were developed be-
fore MRI became widely available. In the present analysis,
we also investigated the possibility of including inflamma-
tory findings on MRI (ASAS definition [9]) as a feature in
both the ESSG and Amor criteria, resulting in the modi-
fied Amor (mAmor) and modified European Spondyloar-
thropathy Study Group (mESSG) criteria.
The ASAS axSpA criteria consist of two arms, the im-
aging arm and the clinical arm, and can be applied only
to patients with back pain of ≥3 months’ duration and
an age of onset <45 years [10]. In patients with sacroilii-
tis visualised on pelvic radiographs or MRI, at least one
other SpA feature should be present in order to be clas-
sified as axSpA according to the imaging arm [4]. In
HLA-B27-positive patients, at least two other additional
SpA features should be present in order to be classified
as axSpA according to the clinical arm [4]. In patients
without current back pain but with current peripheral
manifestations, the classification for peripheral SpA can
be applied. If a patient satisfies the entry criterion
(current arthritis, enthesitis or dactylitis), the patient
should have at least one other SpA feature if this is a
specific SpA feature or at least two SpA features for less
specific features [5]. Altogether, when current back pain
(as defined above) is the presenting symptom, the ASAS
axial SpA criteria should be applied. If arthritis/enthesi-
tis/dactylitis is the presenting symptom, the peripheral
SpA criteria should be applied. Together, these two sets
form the ASAS SpA criteria.
A separate classification criteria set has been developed
for PsA: the CASPAR criteria [6]. To meet the CASPAR
criteria, the stem of the criteria demands first the presence
of inflammatory articular disease and a score of at least 3
points derived from the presence of features such as skin
psoriasis, dactylitis, nail lesions or juxta-articular bone for-
mation visualised on radiographs (each feature is assigned
a certain number of points). All above-described criteria
sets are depicted in Additional file 1.
Data analysis
Disease characteristics were described using descriptive
statistics. The fulfilment of classification criteria was
calculated for the cohort as a whole and thereafter per
region. Subsequently, overlap between the different clas-
sification criteria was investigated and presented in Venn
diagrams. This was done for patients with back pain and
patients without back pain separately. Next, we looked
in detail at the fulfilment of the ASAS axSpA criteria,
comparing patients fulfilling only the clinical arm,
patients fulfilling only the imaging arm and patients
fulfilling both the clinical and imaging arms with regard
to demographics and the presence of SpA features.
Information on HLA-B27 must be available to be able to
classify patients in the ‘imaging arm-only’ group, and
information on imaging must be available to be able to
classify patients in the ‘clinical arm-only’ group. IBM
SPSS Statistics version 20.0 software (IBM, Armonk, NY,
USA) was used for statistical analysis.
Results
In total, 3984 patients were included in the COMOSPA
study, with a mean number of SpA features of 5.5 (SD
1.8). The most common missing items were MRI of the
sacroiliac joints (missing in 1951 patients), the presence of
juxta-articular bone formation (missing in 999 patients)
and HLA-B27 status (missing in 882 patients). There were
251 patients (6.4%) for whom both sacroiliac joint MRI
and radiographs were not performed and 180 patients
(4.6%) for whom HLA-B27 in addition was missing.
On the other hand, information on extra-articular
manifestations was missing in none of the cases.
Arbitrarily, a maximum of 6 missing items (total
number of items 18) per patient was accepted. Pa-
tients with 7 or more missing items (n = 42) were left
out of the analysis, which brings the total number of
patients for this analysis to 3942. To define SpA
features as present or absent, in order to apply the
classification criteria, missing items were regarded as
absent.
Demographics and disease characteristics are depicted
in Table 1. Patients had a mean age of 44 years, and 65%
were male. In the total cohort (patients with available
data), HLA-B27 positivity was seen in 56% (73.0%) of
the patients, and 54% (57.7%) had an elevated C-reactive
protein level. Regarding the presence of sacroiliitis visua-
lised on imaging, 64% (70.0%) presented with sacroiliitis
seen on radiographs and 34% (94.8%) with sacroiliitis
seen on MRI.
Fulfilment of classification criteria
Most (92.6%) of the 3942 patients fulfilled the mESSG
criteria. Fulfilment of Amor, mAmor, ESSG and ASAS
criteria was all above 80% (Table 2). A minority
(12.3%) of the patients fulfilled the ASAS pSpA
criteria, whereas 21.6% of the patients fulfilled the
CASPAR criteria. We emphasise that the criteria were
Bakker et al. Arthritis Research & Therapy  (2017) 19:96 Page 3 of 8
applied to all patients; only the patients with seven or
more missing values were left out, and missing items
were regarded as absent.
Most patients (n = 1507) were included in Western
Europe (85 centres from 26 countries), followed by
1073 patients in Asia, 438 patients in Central Europe,
337 patients in Latin America, 337 patients in North
Africa and 239 patients in North America. Regional
differences in fulfilment of classification criteria are
depicted in Table 3. When we looked in detail at the
ASAS SpA criteria, we found that in Central Europe,
84% of the patients fulfilled the ASAS axial SpA
criteria (ASAS peripheral criteria 5.3%), whereas in
contrast, in North America, 51% of the patients ful-
filled the axial SpA criteria (ASAS peripheral criteria
22.6%). In both Asia and Central Europe, a small mi-
nority of the patients fulfilled the ASAS pSpA criteria,
and the axial complaints were by far the predominant
symptoms. A relatively high percentage of patients
fulfilled the CASPAR criteria in North America
compared with the other regions. Less pronounced
regional differences were seen regarding criteria sets
that cover the whole spectrum of SpA, namely the
Amor and ESSG criteria.
Overlap in classification criteria
Venn diagrams representing the overlap between the
different criteria sets are shown in Figs. 1 and 2.
Figure 1 reveals that the majority of the patients with back
pain were classified by all three criteria sets: Amor, ESSG
and ASAS axSpA criteria (n = 2392 [74.1%]). Most pa-
tients who fulfilled two criteria sets fulfilled both the
ASAS axSpA criteria and the ESSG criteria (n = 268
[8.3%]). Few patients fulfilled only one criteria set. Most of
the patients who were picked up by one criteria set only
were classified by the ASAS axSpA criteria (n = 179 [5.5%]
compared with 1.3% by the ESSG criteria only and 0.2%
by the Amor criteria only). The major overlap of the
criteria points to the typical clinical pattern of SpA the
included patients have.
Regarding the patients without current back pain (per-
ipheral complaints), again substantial overlap between the
criteria was seen (ASAS pSpA, Amor, ESSG, CASPAR)
(Fig. 2). Most of the patients fulfilled all four criteria sets
(n = 224 [31.3%]). Subsequently, 125 patients (17.5%) ful-
filled all criteria, except those for PsA-specific CASPAR
criteria, which is not surprising, because the CASPAR cri-
teria are focussed on the clinical disease PsA and not on
other forms of pSpA. Only six patients (0.8%) fulfilled only
Table 1 Baseline characteristics
Total patients
(n = 3942)
Based on
available data
Number of patients
with missing items
Age at inclusion, years, mean ± SD 43.6 (13.9) 0
Male sex, n (%) 2563 (65.0%) 0
HLA-B27-positive, n (%) 2217 (56.2%) 72.0% 882
IBP, n (%) 3219 (81.7%) 52
Morning stiffness, n (%) 2497 (63.3%) 22
Enthesitis, n (%) 1354 (34.3%) 0
Dactylitis, n (%) 610 (15.5%) 3
Psoriasis, n (%) 843 (21.4%) 0
Uveitis, n (%) 771 (19.6%) 0
Peripheral arthritis, n (%) 2424 (61.5%) 0
IBD, n (%) 209 (5.3%) 0
Positive family history, n (%) 1475 (37.4%) 117
Good response to NSAIDs, n (%) 2433 (61.7%) 77.5% 803
Elevated CRP, n (%) 2109 (53.5%) 57.7% 287
Preceding infection, n (%) 271 (6.9%) 74
Sacroiliitis based on radiograph (mNY), n (%) 2539 (64.4%) 70.0% 341
Sacroiliitis based on MRI, n (%) 1326 (33.6%) 65.7% 1951
Rheumatoid factor-negative, n (%) 3177 (80.6%) 94.8% 613
Psoriatic nail dystrophy, n (%) 460 (11.7%) 28
Juxta-articular bone formation, n (%) 526 (13.3%) 17.7% 999
Abbreviations: IBP Inflammatory back pain according to Assessment of SpondyloArthritis international Society definition (reference), IBD Inflammatory bowel
disease, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, HLA-B27 Human leucocyte antigen, mNY Modified New York criteria, NSAID Non-steroidal anti-
inflammatory drug, MRI Magnetic resonance imaging
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the CASPAR criteria, and only four patients (0.6%) ful-
filled only the ASAS pSpA criteria. Regarding overlap be-
tween the different criteria sets in the different regions,
the same trends were seen, and no substantial inter-
regional differences were found (data not shown).
Comparison between patients fulfilling the ASAS imaging
arm split by presence of HLA-B27 and the clinical arm
only
Disease characteristics of patients fulfilling the im-
aging arm or the clinical arm only are depicted in
Table 4. In addition, characteristics of patients fulfill-
ing the imaging arm are presented on the basis of the
presence or absence of HLA-B27. Only patients who
have data available on HLA-B27 and imaging are in-
cluded in Table 4. There were more male patients in
the HLA-B27-positive imaging arm (74.1%) than in
the HLA-B27-negative imaging arm (50.4%) and the
clinical arm (53.1%). Psoriasis was seen more fre-
quently in the group of HLA-B27-negative patients
fulfilling the imaging arm. On the contrary, enthesitis
and dactylitis were relatively more common in the pa-
tients who fulfilled only the clinical arm. A positive
family history was also more frequently seen in the
clinical arm than in the imaging arm (independent of
HLA-B27 status).
Discussion
Appropriate diagnostic criteria for axSpA and pSpA do
not exist and, in the absence of an unequivocal gold stand-
ard, will never be developed, but various classification
criteria are available. These classification criteria have in
common that they have been developed using the external
standard ‘expert opinion’. But expert opinion is not an
equivocal and homogeneous construct and may poten-
tially integrate different pictures of the disease SpA.
The present study reveals that, in our cohort, most
patients diagnosed as having SpA fulfilled multiple clas-
sification criteria sets, which adds to the credibility of
the construct of SpA as a recognizable entity. Although
the substantial overlap between the different criteria sets
for patients with both axial and with peripheral symp-
toms could be expected, the fact that different criteria
sets have been developed for different target populations
(e.g., the ESSG, focussed on the whole concept of SpA;
the ASAS axial SpA criteria for patients with SpA axial
symptoms) could have precluded overlap in different re-
gions of the world. In the present study, we have shown
that the significant overlap was consistent all over the
world, thus suggesting that rheumatologists worldwide
use similar ‘pictures’ of what SpA is. In other words,
Table 2 Fulfilment of classification criteria
Classification criteria Patients who fulfilled the
classification criteria, n (%)
Amor 3282 (83.3%)
mAmor 3454 (87.6%)
ESSG 3485 (88.4%)
mESSG 3652 (92.6%)
ASAS SpA total 3370 (85.5%)
ASAS axial SpA, current back pain 2955 (87.7%)
Both arms (imaging & clinical) 1737 (58.8%)
mNY+ 976 (56.2%)
MRI+ 169 (9.7%)
Both 592 (34.1%)
Imaging arm only 984 (33.3%)
mNY+ 539 (54.8%)
MRI+ 245 (24.9%)
Both 200 (20.3%)
Clinical arm only 234 (7.9%)
ASAS peripheral SpA 415 (12.3%)
CASPAR 852 (21.6%)
Abbreviations: mAmor Modified Amor, ESSG European Spondylarthropathy
Study Group, mESSG Modified European Spondyloarthropathy Study Group,
ASAS Assessment of SpondyloArthritis international Society, mNY Modified
New York, MRI Magnetic resonance imaging, CASPAR ClASsification criteria for
Psoriatic ARthritis
Table 3 Regional differences in fulfilment of classification criteria
Number
of patients
included
Patients
fulfilling Amor
criteria, n (%)
Patients
fulfilling mAmor
criteria, n (%)
Patients
fulfilling ESSG
criteria, n (%)
Patients
fulfilling mESSG
criteria, n (%)
Total patients
fulfilling ASAS
SpA criteria, n (%)
Patients fulfilling
ASAS axSpA
criteria, n (%)
Patients fulfilling,
ASAS pSpA
criteria, n (%)
Patients
fulfilling CASPAR
criteria, n (%)
Western Europe 1507 1242 (82.4%) 1333 (88.5%) 1335 (88.6%) 1433 (95.1%) 1305 (86.6%) 1149 (76.2%) 156 (10.4%) 388 (25.7%)
Central Europe 438 342 (78.1%) 364 (83.1%) 402 (91.8%) 419 (95.7%) 391 (89.3%) 368 (84.0%) 23 (5.3%) 32 (7.3%)
North America 239 203 (84.9%) 205 (85.8%) 219 (91.6%) 219 (91.6%) 176 (73.6%) 122 (51.0%) 54 (22.6%) 120 (50.2%)
Latin America 348 290 (83.3%) 307 (88.2%) 314 (90.2%) 326 (93.7%) 280 (80.5%) 239 (68.7%) 41 (11.8%) 93 (26.7%)
North Africa 337 300 (89.0%) 310 (92.0%) 316 (93.8%) 324 (96.1%) 308 (91.4%) 260 (77.2%) 48 (14.2%) 94 (27.9%)
Asia 1073 905 (84.3%) 935 (87.1%) 899 (83.8%) 931 (86.8%) 910 (84.8%) 817 (76.1%) 93 (8.7%) 125 (11.6%)
Abbreviations: ASAS Assessment of SpondyloArthritis international Society, axSpA Axial spondyloarthritis, CASPAR ClASsification criteria for Psoriatic Arthritis, ESSG European
Spondyloarthropathy Study Group, mAmor Modified Amor, mESSG Modified European Spondyloarthropathy Study Group, pSpA Peripheral spondyloarthritis,
SpA Spondyloarthritis
Percentages relate to number of patients of that specific region
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they operationalise the construct of SpA approximately
similarly. In addition, the huge overlap (e.g., 74.1% of the
patients fulfilled all three criteria sets, and only 7.6%
fulfilled one set only) confirms that the criteria for SpA
are highly credible.
As mentioned already, large interregional differences
in the fulfilment of classification criteria were not found.
This is remarkable in the light of all genetic and envir-
onmental differences, as well as differences in resources
and health care systems around the world. In fact, it ap-
pears that the clinical picture—and consequently the
diagnosis—of SpA is remarkably homogeneous around
the world, despite all possible differences in, for example,
genetic background, prevalence and medical training.
Of course, there were some notable differences. The
most important one was that more patients with PsA and
fewer patients with axial disease were included in North
America than in other regions. We do not think this re-
flects a true difference in the prevalence of the different
subtypes of the disease. This is supported by a recent
systematic review that pooled population prevalence esti-
mates for SpA, AS and PsA in geographic areas [11]. The
prevalence of both the axial and peripheral subtypes was,
on average, comparable in North America to other parts
of the world. More likely, the difference could be due to
local factors, such as a difference in areas of interest of the
doctors including patients or referral centres for a certain
disease. One reason may be the perception of PsA as be-
longing to SpA or not. It is well known that some rheuma-
tologists view PsA as a separate entity and others view
PsA as a subtype of SpA. Apparently, more doctors in
North America than in other parts of the world consider
patients with PsA as having SpA.
Regarding the inclusion criteria of the study, doctors
were required to include patients with SpA only if they
thought the patient would fulfil the ASAS SpA criteria
(either peripheral or axial). However, fulfilment of the
ASAS criteria was not formally checked before inclusion,
as described in the Methods section above. When ana-
lysing the data, it became clear that only 85.5% of the
patients actually did fulfil the ASAS SpA criteria, ran-
ging from 73.6% in North America to 91.4% in North
Africa. This implies that the large majority of patients
with SpA are indeed covered by the criteria, pointing to
high sensitivity but also indicating that doctors diagnose
SpA in patients who do not fulfil the ASAS criteria.
However, we would like to make a critical comment
which relates to a limitation of the present study. The
fact that rheumatologists were initially asked to include
Fig. 1 Overlap between ESSG, AMOR, and axSpA criteria in patients
with current back pain (n = 3227)
Fig. 2 Overlap between the ESSG, AMOR, CASPAR, and pSpA criteria in patients without current back pain (n = 715)
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ASAS SpA patients (although fulfilment of the ASAS
criteria was not met in all patients) could very well have
led to an ‘a priori’ high percentage of ASAS classification
criteria fulfilment. This could have led to an overesti-
mation of performance of sensitivity of the criteria.
The ASAS classification criteria were developed in re-
cent history. The criteria were validated in an inter-
national study of more than 600 patients with chronic
back pain of unknown origin. In the ASAS study popula-
tion, the ASAS criteria compared favourably with other
previously established criteria sets with regard to sensi-
tivity and specificity. In our study, if patients with axial
symptoms were picked up by one criteria set only, of all
sets tested, the ASAS axSpA criteria were most sensitive
(although the others performed well, too). The latter
could be due to the fact that the ASAS-COMOSPA
study is not a cohort of early disease (as reflected by
65% modified New York criteria positivity). Prior studies
have shown that performances of, for example, ESSG
and Amor criteria in early disease were (slightly) worse
than the ASAS criteria [12]. A more likely explanation is
that the rheumatologists were asked to include patients
fulfilling the ASAS criteria.
Although the imaging arm of the ASAS classification
criteria is broadly recognized as highly specific, there has
been debate on the validity of the clinical arm of the
ASAS criteria, which has not been well received by dif-
ferent national and international health care systems. In
the literature, it has been argued that patients fulfilling
only the clinical arm of the ASAS axSpA criteria should
not be considered as having ‘true axSpA’. A reason why
the clinical arm of the ASAS axSpA criteria has been de-
veloped is that MRI is not universally available. In our
cohort, in which a large proportion of patients did not
undergo MRI, our results demonstrate the value of the
clinical arm of the ASAS criteria for scientific research.
We found that patients fulfilling the clinical arm were
remarkably similar to patients fulfilling the imaging arm
with respect to the presence of many SpA features.
Strengths of the study are the multi-national cohort
and the large number of patients included, which is
unique, to our knowledge. Unfortunately, no control
group was available, and therefore true specificity of the
different classification criteria sets could not be calcu-
lated. Another limitation of the study is the relatively
high number of missing values, especially when it comes
to key items such as HLA-B27 and MRI. Unfortunately,
this is a direct consequence of normal clinical practice:
If sufficient information has been collected to make a
diagnosis, further testing is often not performed (e.g., to
save expenses).
We can conclude that, despite the heterogeneous char-
acter and varying prevalence of SpA as a disease across
the world, similar patients are identified as having SpA
by rheumatologists worldwide. Moreover, patients with
the diagnosis of SpA usually fulfil multiple criteria sets,
providing validity to the criteria, including the relatively
new ASAS SpA criteria as well as to the concept of SpA.
We emphasize that classification criteria for SpA were
developed for use in epidemiological and clinical re-
search and are not suitable for use as diagnostic tools in
clinical practice.
Table 4 Comparison between the imaging arm and clinical arm of the ASAS axSpA criteria, with the required presence of HLA-B27
and imaging
Imaging arm (%), HLA-B27 always available Clinical arm alone (%), imaging
always available (n = 98)HLA-B27-positive (n = 1746) HLA-B27-negative (n = 546)
Age, years 40.3 (13.0) 42.7 (13.0) 42.8 (13.0)
Male sex 1294 (74.1%) 275 (50.4%) 52 (53.1)
IBP 1639 (93.3%) 529 (96.9%) 87 (88.8%)
Peripheral arthritis 904 (51.8%) 302 (55.3%) 57 (58.2%)
Psoriasis 147 (8.4%) 105 (19.2%) 14 (14.3%)
Uveitis 453 (25.9%) 49 (9.0%) 27 (27.6%)
Enthesitis 563 (32.2%) 164 (30.0%) 44 (44.9%)
Dactylitis 137 (7.8%) 55 (10.1%) 17 (17.3%)
IBD 73 (4.2%) 46 (8.4%) 6 (6.1%)
Positive family history 669 (38.3%) 166 (30.4%) 52 (53.1%)
Good response to NSAIDs 1180 (67.6%) 265 (48.5%) 64 (65.3%)
Elevated CRP 1094 (62.7%) 256 (46.9%) 41 (41.8%)
Abbreviations: HLA-B27 Human leucocyte antigen B27, IBP Inflammatory back pain, IBD Inflammatory bowel disease, NSAID Non-steroidal anti-inflammatory drug,
CRP C-reactive protein
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Conclusions
Most patients diagnosed with SpA by rheumatologists in
five continents across the world fulfilled multiple classi-
fication criteria sets. To our knowledge, this is the first
study confirming the validity of the ASAS axSpA criteria
in a large, worldwide population of patients. Patients ful-
filling the clinical and/or imaging arms of the ASAS
axSpA criteria have comparable SpA features.
For the first time, to our knowledge, the performance
of the various SpA classification criteria sets is assessed
in a worldwide setting with a very large number of
patients included from five different continents. We also
took the opportunity to phenotypically compare patients
fulfilling the different arms of the ASAS axial SpA
criteria in terms of demographics and presence of SpA
features, among others.
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